Compare SBET & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | PHAR |
|---|---|---|
| Founded | 1995 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 885.7M |
| IPO Year | 2025 | 2020 |
| Metric | SBET | PHAR |
|---|---|---|
| Price | $5.67 | $14.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $18.71 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 10.5M | 4.4K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $105.19 | $10.04 |
| Revenue Next Year | $13.53 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $4.46 | $9.54 |
| 52 Week High | $40.46 | $21.34 |
| Indicator | SBET | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 62.60 |
| Support Level | $5.06 | $12.98 |
| Resistance Level | $6.09 | $14.81 |
| Average True Range (ATR) | 0.34 | 0.39 |
| MACD | 0.10 | 0.21 |
| Stochastic Oscillator | 72.70 | 100.00 |
SharpLink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.